Pepcid AC Gelcaps Sample Pouch Deferral Granted Without "Drug Facts" Title
This article was originally published in The Tan Sheet
J&J/Merck's request for a nine-month deferral from complying with the OTC labeling format for sample pouches of the company's H2 antagonist Pepcid AC Gelcaps has been granted.
You may also be interested in...
FDA will publish a notice to "delay the compliance date of the current Drug Facts rules with respect to 'convenience-size' drug packages" in an upcoming issue of the Federal Register
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products
Block Drug's request for an exemption from the OTC labeling final rule for its BC analgesic powder complies with provisions of the FD&C Act that differentiate a product's "label" from product "labeling," the company says in a Dec. 22 letter to FDA.